2026-04-17T05:56:52Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/107662025-10-24T10:41:48Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Villamarín Melio, Miguel author Len, Oscar author 2024-01-08T10:43:27Z 2024-01-08T10:43:27Z 2023-11 SARS-CoV-2 infection; Transplant recipients; Solid organ Infecció per SARS-CoV-2; Receptors de trasplantament; Òrgans sòlids Infección por SARS-CoV-2; Receptores de trasplantes; Órganos sólidos Solid organ transplant recipients (SOTR) constitute one of the groups at highest risk for the development of severe COVID-19. However, evidence on the effectiveness of treatments for SARS-CoV-2 infection in this group of patients is scarce. Molnupiravir is an orally administered antiviral drug that has demonstrated effectiveness in reducing the risk of progression to severe COVID-19 in high-risk outpatients, mainly in the unvaccinated population. Although its effectiveness is lower than that of other antivirals, on many occasions it is the only therapeutic option in transplant recipients given the absence of pharmacological interactions with immunosuppressive treatment, the oral route of administration and the good safety profile. http://hdl.handle.net/11351/10766 COVID-19 (Malaltia) Trasplantació d'òrgans, teixits, etc. DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections NAMED GROUPS::Persons::Transplant Recipients ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Transplantation::Organ Transplantation ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus DENOMINACIONES DE GRUPOS::personas::receptores de trasplantes TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::trasplante::trasplante de órganos SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir